Nasal Cavity and Paranasal Sinus Cancer

Nasal cavity and paranasal sinus cancers are malignant tumors arising from the nasal cavity and the four paired paranasal sinuses:

• Frontal sinuses.

• Ethmoid sinuses.

• Maxillary sinuses.

• Sphenoid sinuses.

These tumors represent a heterogeneous group of malignancies with different histological characteristics and clinical behaviors. Due to the anatomical complexity of the region and the late appearance of symptoms, many patients present with locally advanced disease.

Management requires a multidisciplinary approach involving surgery, radiotherapy, and chemotherapy depending on disease stage and patient factors.

Epidemiology

Nasal cavity and paranasal sinus cancers are uncommon head and neck malignancies. They occur in both males and females and are frequently diagnosed at advanced stages due to nonspecific early symptoms.

The maxillary sinus is among the commonly affected sites because of its size and delayed symptom development.

Risk factors

Risk factors associated with nasal cavity and paranasal sinus cancers include:

• Occupational exposure to wood dust.

• Exposure to industrial chemicals.

• Tobacco exposure.

• Previous radiation exposure.

• Chronic inflammation of nasal mucosa.

• Human papillomavirus (HPV) infection.

• Genetic predisposition.

Pathophysiology

Nasal cavity and paranasal sinus cancers develop from malignant transformation of epithelial cells lining the nasal cavity or sinus mucosa.

Tumor progression may involve:

• Local invasion into surrounding structures.

• Extension into the orbit causing eye symptoms.

• Invasion of facial structures.

• Skull base involvement.

• Cervical lymph node metastasis.

• Distant metastasis in advanced disease.

The pattern of spread depends on the tumor site and histological subtype.

Clinical presentation

Clinical presentation depends on:

• The anatomical site of origin.

• Tumor size.

• Extent of local invasion.

• Involvement of surrounding structures.

Because the sinuses are air-filled spaces, tumors may grow significantly before causing symptoms.

Symptoms

Common symptoms include:

• Nasal obstruction.

• Epistaxis (nose bleeding).

• Proptosis (eye protrusion).

• Double vision.

• Cheek mass.

• Loss of sensation of the cheek.

• Loosening of teeth.

• Tooth pain.

• Facial pain or pressure.

Clinical signs

Clinical findings may include:

• Nasal cavity mass.

• Facial swelling.

• Proptosis.

• Eye movement abnormalities.

• Reduced facial sensation.

• Dental abnormalities.

• Cervical lymphadenopathy.

Differential diagnosis

Conditions that may mimic nasal cavity and paranasal sinus cancer include:

• Chronic sinusitis.

• Nasal polyps.

• Benign sinonasal tumors.

• Fungal sinus infection.

• Nasopharyngeal carcinoma.

• Lymphoma.

• Dental infections involving the maxillary sinus.

Diagnostic criteria

Nasal cavity and paranasal sinus cancer should be suspected in patients presenting with:

• Persistent nasal obstruction.

• Recurrent epistaxis.

• Facial swelling.

• Eye symptoms such as proptosis or double vision.

• Persistent cheek numbness.

• Unexplained dental loosening or pain.

Definitive diagnosis requires histopathological confirmation from biopsy.

Investigations

Laboratory investigations

• Full blood count (FBC).

• Renal function tests (RFT).

• Liver function tests (LFT).

Imaging investigations

• Chest X-ray (CXR).

• Abdominal ultrasound.

• Computed tomography (CT) scan of:

  • Paranasal sinuses.

  • Neck.

• Magnetic resonance imaging (MRI) of:

  • Paranasal sinuses.

  • Neck.

Imaging assesses:

• Tumor size.

• Local invasion.

• Orbital involvement.

• Skull base involvement.

• Lymph node disease.

Endoscopic evaluation

• Direct fibre-optic endoscopy.

Histopathological investigation

• Endoscopic-guided biopsy of the primary tumor for histopathology.

Diagnostic staging

Nasal cavity and paranasal sinus cancers are staged using:

• TNM staging system.

Management

Management depends on:

• Tumor site.

• Histological type.

• Disease stage.

• Resectability.

• Patient general condition.

Treatment options include:

• Surgery.

• Radiotherapy.

• Chemotherapy.

Treatment may involve:

• Single modality therapy.

• Combined treatment approaches.

Non-pharmacological treatment

Surgery

Surgical resection is an important component of treatment, particularly in resectable disease.

Surgery may include:

• Complete surgical resection of the primary tumor.

Neck dissection may be performed for:

• Clinically involved cervical lymph nodes.

• Persistently enlarged lymph nodes.

• Persistent or recurrent disease after radiotherapy.

Early-stage disease (Stage I–II N0)

Management options include:

• Complete surgical resection followed by radiotherapy.

OR

• Definitive radiotherapy.

Radiotherapy

Radiotherapy may be used:

• As adjuvant treatment after surgery.

• As definitive treatment when surgery is not appropriate.

• In combination with chemotherapy.

• As palliative treatment for advanced disease.

Chemoradiotherapy

Radiotherapy may be combined with chemotherapy depending on:

• Disease stage.

• Tumor characteristics.

• Treatment objectives.

Pharmacological treatment

(No chemotherapy drugs or specific dosing schedules were provided in the source information; therefore, no additional drug regimens are added.)

Chemotherapy may be used in:

• Induction therapy.

• Concurrent chemoradiotherapy.

• Adjuvant therapy.

• Advanced disease management.

Management according to disease stage

Stage I–II, N0 disease

Treatment options:

• Complete surgical resection followed by radiotherapy.

OR

• Definitive radiotherapy.

Locally advanced disease

Management may include:

• Surgery followed by radiotherapy.

• Definitive radiotherapy with or without chemotherapy.

Persistent or recurrent disease

Management options include:

• Surgical resection where feasible.

• Neck dissection for persistent lymph node disease.

• Radiotherapy.

• Chemotherapy.

Advanced disease

Management:

• Palliative radiotherapy.

• Systemic therapy where indicated.

• Supportive care.

Referral

All patients with suspected or confirmed nasal cavity or paranasal sinus cancer should be referred to a specialized head and neck oncology center for:

• Endoscopic assessment.

• Histological confirmation.

• TNM staging.

• Multidisciplinary treatment planning.

Urgent referral is required for:

• Persistent nasal obstruction.

• Recurrent epistaxis.

• Facial swelling.

• Orbital symptoms.

• Facial numbness.

Complications

Complications may include:

• Orbital invasion.

• Visual impairment.

• Facial deformity.

• Cranial nerve involvement.

• Cervical lymph node metastasis.

• Distant metastasis.

• Local recurrence.

• Treatment-related complications.

Prognosis

Prognosis depends on:

• Disease stage at diagnosis.

• Tumor location.

• Histological subtype.

• Extent of local invasion.

• Presence of lymph node or distant metastases.

• Response to treatment.

Early-stage disease has better outcomes compared with advanced tumors involving surrounding structures.

Prevention

Preventive strategies include:

• Avoidance of occupational carcinogen exposure.

• Use of appropriate protective equipment in high-risk workplaces.

• Avoidance of tobacco exposure.

• Early evaluation of persistent nasal symptoms.

• Prompt investigation of suspicious sinonasal lesions.

Follow-up

Patients require regular follow-up after treatment to assess:

• Local recurrence.

• Regional lymph node recurrence.

• Distant metastasis.

• Treatment complications.

Follow-up may include:

• Clinical examination.

• Nasal endoscopic assessment.

• Imaging studies when clinically indicated.